A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic peripheral neuropathy.
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2014
At a glance
- Drugs CNV 2197944 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Peripheral neuropathies
- Focus Therapeutic Use
- Sponsors Convergence Pharmaceuticals
- 27 Sep 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 28 Jan 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 08 Jul 2013 Status changed to recruiting according to a Convergence Pharmaceuticals media release.